1
|
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, Cohen-Jonathan Moyal E, Bronnimann C, Di Stefano AL, Laurent I, Lerond J, Carpentier C, Bielle F, Ducray F, Dehais C. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas. Eur J Cancer 2024; 202:114034. [PMID: 38537315 DOI: 10.1016/j.ejca.2024.114034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2024] [Accepted: 03/20/2024] [Indexed: 04/21/2024]
Abstract
BACKGROUND Novel effective treatments are needed for recurrent IDH mutant high-grade gliomas (IDHm HGGs). The aim of the multicentric, single-arm, phase II REVOLUMAB trial (NCT03925246) was to assess the efficacy and safety of the anti-PD1 Nivolumab in patients with recurrent IDHm HGGs. PATIENTS AND METHODS Adult patients with IDHm WHO grade 3-4 gliomas recurring after radiotherapy and ≥ 1 line of alkylating chemotherapy were treated with intravenous Nivolumab until end of treatment (12 months), progression, unacceptable toxicity, or death. The primary endpoint was the 24-week progression-free survival rate (24w-PFS) according to RANO criteria. RESULTS From July 2019 to June 2020, 39 patients with recurrent IDHm HGGs (twenty-one grade 3, thirteen grade 4, five grade 2 with radiological evidence of anaplastic transformation; 39% 1p/19q codeleted) were enrolled. Median time since diagnosis was 5.7 years, and the median number of previous systemic treatments was two. The 24w-PFS was 28.2% (11/39, CI95% 15-44.9%). Median PFS and OS were 1.84 (CI95% 1.81-5.89) and 14.7 months (CI95% 9.18-NR), respectively. Four patients (10.3%) achieved partial response according to RANO criteria. There were no significant differences in clinical or histomolecular features between responders and non-responders. The safety profile of Nivolumab was consistent with prior studies. CONCLUSIONS We report the results of the first trial of immune checkpoint inhibitors in IDHm gliomas. Nivolumab failed to achieve its primary endpoint. However, treatment was well tolerated, and long-lasting responses were observed in a subset of patients, supporting further evaluation in combination with other agents (e.g. IDH inhibitors).
Collapse
Affiliation(s)
- Alberto Picca
- Service de Neuro-oncologie, Institut de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France
| | - Mehdi Touat
- Service de Neuro-oncologie, Institut de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France
| | - Lisa Belin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département de Santé Publique, Unité de Recherche Clinique PSL-CFX, CIC-1901, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Carole Gourmelon
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France
| | - Vincent Harlay
- Department of Neuro-Oncology, AP-HM, University Hospital Timone, Marseille, France
| | - Stefania Cuzzubbo
- Department of Neurology, Hôpital Saint-Louis, Université Paris Cité, APHP, Paris, France
| | - Elizabeth Cohen-Jonathan Moyal
- Department of Radiotherapy, Oncopole Claudius Regaud, Cancer University Institute of Toulouse, Oncopole Paul Sabatier University, Toulouse III, Cancer Research Center of Toulouse (CRCT), Toulouse, France
| | - Charlotte Bronnimann
- Hôpital Saint-André Bordeaux, Centre Hospitalier Universitaire, Service d'Oncologie, 33000 Bordeaux, France
| | - Anna Luisa Di Stefano
- Department of Neurology, Foch Hospital, 92150 Suresnes, France; Division of Neurosurgery, Spedali Riuniti di Livorno-USL Toscana Nord-Ovest, 57124 Livorno, Italy
| | - Isaura Laurent
- Unité de Recherche Clinique PSL-CFX, CIC-1901, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Julie Lerond
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France
| | - Catherine Carpentier
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France
| | - Franck Bielle
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France; Department of Neuropathology, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - François Ducray
- Department of Neuro-Oncology, East Group Hospital, Hospices Civils de Lyon, Lyon, France
| | - Caroline Dehais
- Service de Neuro-oncologie, Institut de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France.
| |
Collapse
|
2
|
Lerond J, Mathon B, Scopin M, Nichelli L, Guégan J, Bertholle C, Izac B, Andrieu M, Gareau T, Donneger F, Mohand Oumoussa B, Letourneur F, Tran S, Bertrand M, Le Roux I, Touat M, Dupont S, Poncer JC, Navarro V, Bielle F. Hippocampal and neocortical BRAF mutant non-expansive lesions in focal epilepsies. Neuropathol Appl Neurobiol 2023; 49:e12937. [PMID: 37740653 DOI: 10.1111/nan.12937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 08/31/2023] [Accepted: 09/18/2023] [Indexed: 09/24/2023]
Abstract
OBJECTIVE Mesial Temporal Lobe Epilepsy-associated Hippocampal Sclerosis (MTLE-HS) is a syndrome associated with various aetiologies. We previously identified CD34-positive extravascular stellate cells (CD34+ cells) possibly related to BRAFV600E oncogenic variant in a subset of MTLE-HS. We aimed to identify the BRAFV600E oncogenic variants and characterise the CD34+ cells. METHODS We analysed BRAFV600E oncogenic variant by digital droplet Polymerase Chain Reaction in 53 MTLE-HS samples (25 with CD34+ cells) and nine non-expansive neocortical lesions resected during epilepsy surgery (five with CD34+ cells). Ex vivo multi-electrode array recording, immunolabelling, methylation microarray and single nuclei RNAseq were performed on BRAFwildtype MTLE-HS and BRAFV600E mutant non-expansive lesion of hippocampus and/or neocortex. RESULTS We identified a BRAFV600E oncogenic variant in five MTLE-HS samples with CD34+ cells (19%) and in five neocortical samples with CD34+ cells (100%). Single nuclei RNAseq of resected samples revealed two unique clusters of abnormal cells (including CD34+ cells) associated with senescence and oligodendrocyte development in both hippocampal and neocortical BRAFV600E mutant samples. The co-expression of the oncogene-induced senescence marker p16INK4A and the outer subventricular zone radial glia progenitor marker HOPX in CD34+ cells was confirmed by multiplex immunostaining. Pseudotime analysis showed that abnormal cells share a common lineage from progenitors to myelinating oligodendrocytes. Epilepsy surgery led to seizure freedom in eight of the 10 patients with BRAF mutant lesions. INTERPRETATION BRAFV600E underlies a subset of MTLE-HS and epileptogenic non-expansive neocortical focal lesions. Detection of the oncogenic variant may help diagnosis and open perspectives for targeted therapies.
Collapse
Affiliation(s)
- Julie Lerond
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Sorbonne Université, Paris, France
| | - Bertrand Mathon
- AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Department of Neurosurgery, Sorbonne Université, Paris, France
| | - Mélina Scopin
- Institut du Fer à Moulin, Inserm, Sorbonne Université, Paris, France
| | - Lucia Nichelli
- AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Department of Neuroradiology, Sorbonne Université, Paris, France
| | - Justine Guégan
- Institut du Cerveau-Paris Brain Institute-ICM-Data Analysis Core platform, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Sorbonne Université, Paris, France
| | - Céline Bertholle
- CNRS, INSERM, Institut Cochin, Université Paris Cité, Paris, France
| | - Brigitte Izac
- CNRS, INSERM, Institut Cochin, Université Paris Cité, Paris, France
| | - Muriel Andrieu
- CNRS, INSERM, Institut Cochin, Université Paris Cité, Paris, France
| | - Thomas Gareau
- Institut du Cerveau-Paris Brain Institute-ICM-Data Analysis Core platform, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Sorbonne Université, Paris, France
| | - Florian Donneger
- Institut du Fer à Moulin, Inserm, Sorbonne Université, Paris, France
| | - Badreddine Mohand Oumoussa
- Inserm, UMS Production et Analyse des données en Sciences de la vie et en Santé, PASS, Plateforme Post-génomique de la Pitié-Salpêtrière, Sorbonne Université, Paris, France
| | | | - Suzanne Tran
- AP-HP, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Department of Neuropathology, Sorbonne Université, Paris, France
| | - Mathilde Bertrand
- Institut du Cerveau-Paris Brain Institute-ICM-Data Analysis Core platform, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Sorbonne Université, Paris, France
| | - Isabelle Le Roux
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Sorbonne Université, Paris, France
| | - Mehdi Touat
- AP-HP, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Department of Neurology 2-Mazarin, Sorbonne Université, Paris, France
| | - Sophie Dupont
- IAP-HP, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière, Rehabilitation Unit, Sorbonne Université, Paris, France
| | | | - Vincent Navarro
- AP-HP, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Epilepsy Unit, Department of Neurology and EEG Unit, Department of Clinical Neurophysiology, Reference Center for Rare Epilepsies, Sorbonne Université, Paris, France
| | - Franck Bielle
- AP-HP, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Department of Neuropathology, Sorbonne Université, Paris, France
- AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Onconeurotek, Paris, France
| |
Collapse
|
3
|
Tran S, Thomas A, Aliouat I, Karachi C, Lozano F, Mokhtari K, Dehais C, Feuvret L, Carpentier C, Giry M, Doukani A, Lerond J, Marie Y, Sanson M, Idbaih A, Carpentier A, Hoang-Xuan K, Touat M, Capelle L, Bielle F. A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant. Neuropathol Appl Neurobiol 2023; 49:e12928. [PMID: 37503540 DOI: 10.1111/nan.12928] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 07/13/2023] [Accepted: 07/22/2023] [Indexed: 07/29/2023]
Abstract
AIMS The distinction between CNS WHO grade 2 and grade 3 is instrumental in choosing between observational follow-up and adjuvant treatment for resected astrocytomas IDH-mutant. However, the criteria of CNS WHO grade 2 vs 3 have not been updated since the pre-IDH era. METHODS Maximal mitotic activity in consecutive high-power fields corresponding to 3 mm2 was examined for 118 lower-grade astrocytomas IDH-mutant. The prognostic value for time-to-treatment (TTT) and overall survival (OS) of mitotic activity and other putative prognostic factors (including age, performance status, pre-surgical tumour volume, multilobar involvement, post-surgical residual tumour volume and midline involvement) was assessed for tumours with ATRX loss and the absence of CDKN2A homozygous deletion or CDK4 amplification, contrast enhancement, histological necrosis and microvascular proliferation. RESULTS Seventy-one per cent of the samples had <6 mitoses per 3 mm2 . Mitotic activity, residual volume and multilobar involvement were independent prognostic factors of TTT. The threshold of ≥6 mitoses per 3 mm2 identified patients with a shorter TTT (median 18.5 months). A residual volume ≥1 cm3 also identified patients with a shorter TTT (median 24.5 months). The group defined by <6 mitoses per 3 mm2 and a residual volume <1 cm3 had the longest TTT (median 73 months) and OS (100% survival at 7 years). These findings were confirmed in a validation cohort of 52 tumours. CONCLUSIONS Mitotic activity and post-surgical residual volume can be combined to evaluate the prognosis for patients with resected astrocytomas IDH-mutant. Patients with <6 mitoses per 3 mm2 and a residual volume <1 cm3 were the best candidates for observational follow-up.
Collapse
Affiliation(s)
- Suzanne Tran
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neuropathology, Paris, France
| | - Alice Thomas
- Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Ilyes Aliouat
- Department of Neurosurgery, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Paris, France
| | - Carine Karachi
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Department of Neurosurgery, Paris, France
| | - Fernando Lozano
- AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France
| | - Karima Mokhtari
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neuropathology, Paris, France
| | - Caroline Dehais
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France
| | - Loïc Feuvret
- AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Department of Radiotherapy, Paris, France
| | - Catherine Carpentier
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France
| | - Marine Giry
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France
| | - Abiba Doukani
- Sorbonne Université, Inserm, UMS Production et Analyse des données en Sciences de la vie et en Santé, PASS, Plateforme Post-génomique Pitié-Salpêtrière, P3S, Paris, France
| | - Julie Lerond
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France
- Sorbonne Université, AP-HP, Paris, France
| | - Yannick Marie
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France
| | - Marc Sanson
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France
- Sorbonne Université, AP-HP, Paris, France
- Department of Neuropathology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
| | - Ahmed Idbaih
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France
| | - Alexandre Carpentier
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Department of Neurosurgery, Paris, France
| | - Khê Hoang-Xuan
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France
| | - Mehdi Touat
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France
| | - Laurent Capelle
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Department of Neurosurgery, Paris, France
| | - Franck Bielle
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neuropathology, Paris, France
- Sorbonne Université, AP-HP, Paris, France
- Department of Neuropathology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
| |
Collapse
|
4
|
Migliozzi S, Oh YT, Hasanain M, Garofano L, D'Angelo F, Najac RD, Picca A, Bielle F, Di Stefano AL, Lerond J, Sarkaria JN, Ceccarelli M, Sanson M, Lasorella A, Iavarone A. Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. Nat Cancer 2023; 4:181-202. [PMID: 36732634 PMCID: PMC9970878 DOI: 10.1038/s43018-022-00510-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Accepted: 12/21/2022] [Indexed: 02/04/2023]
Abstract
Despite producing a panoply of potential cancer-specific targets, the proteogenomic characterization of human tumors has yet to demonstrate value for precision cancer medicine. Integrative multi-omics using a machine-learning network identified master kinases responsible for effecting phenotypic hallmarks of functional glioblastoma subtypes. In subtype-matched patient-derived models, we validated PKCδ and DNA-PK as master kinases of glycolytic/plurimetabolic and proliferative/progenitor subtypes, respectively, and qualified the kinases as potent and actionable glioblastoma subtype-specific therapeutic targets. Glioblastoma subtypes were associated with clinical and radiomics features, orthogonally validated by proteomics, phospho-proteomics, metabolomics, lipidomics and acetylomics analyses, and recapitulated in pediatric glioma, breast and lung squamous cell carcinoma, including subtype specificity of PKCδ and DNA-PK activity. We developed a probabilistic classification tool that performs optimally with RNA from frozen and paraffin-embedded tissues, which can be used to evaluate the association of therapeutic response with glioblastoma subtypes and to inform patient selection in prospective clinical trials.
Collapse
Affiliation(s)
- Simona Migliozzi
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Young Taek Oh
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Mohammad Hasanain
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Luciano Garofano
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Fulvio D'Angelo
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Ryan D Najac
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA
| | - Alberto Picca
- AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neurologie 2, Paris, France.,Sorbonne Université, INSERM Unité 1127, CNRS UMR 7225, Paris Brain Institute, Equipe labellissée LNCC, Paris, France
| | - Franck Bielle
- Sorbonne Université, INSERM Unité 1127, CNRS UMR 7225, Paris Brain Institute, Equipe labellissée LNCC, Paris, France.,Department of Neuropathology, Pitié-Salpêtrière-Charles Foix, AP-HP, Paris, France
| | - Anna Luisa Di Stefano
- Sorbonne Université, INSERM Unité 1127, CNRS UMR 7225, Paris Brain Institute, Equipe labellissée LNCC, Paris, France.,Department of Neurology, Foch Hospital, Suresnes, Paris, France.,Neurosurgery Unit, Spedali Riuniti, Livorno, Italy
| | - Julie Lerond
- Sorbonne Université, INSERM Unité 1127, CNRS UMR 7225, Paris Brain Institute, Equipe labellissée LNCC, Paris, France
| | - Jann N Sarkaria
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
| | - Michele Ceccarelli
- Department of Electrical Engineering and Information Technology (DIETI), University of Naples Federico II, Napoli, Italy.,BIOGEM Institute of Molecular Biology and Genetics, Via Camporeale, Ariano Irpino, Italy
| | - Marc Sanson
- AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neurologie 2, Paris, France.,Sorbonne Université, INSERM Unité 1127, CNRS UMR 7225, Paris Brain Institute, Equipe labellissée LNCC, Paris, France.,Onconeurotek Tumor Bank, Paris Brain Institute ICM, Paris, France
| | - Anna Lasorella
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA. .,Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA. .,Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA. .,Department of Pediatrics, Columbia University Medical Center, New York, NY, USA. .,Department of Biochemistry and Molecular Biology, University of Miami, Miller School of Medicine, Miami, FL, USA.
| | - Antonio Iavarone
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA. .,Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA. .,Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA. .,Department of Neurology, Columbia University Medical Center, New York, NY, USA. .,Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.
| |
Collapse
|
5
|
Di Stefano AL, Nichelli L, Berzero G, Valabregue R, Touat M, Capelle L, Pontoizeau C, Bielle F, Lerond J, Giry M, Villa C, Baussart B, Dehais C, Galanaud D, Baldini C, Savatovsky J, Dhermain F, Deelchand DK, Ottolenghi C, Lehéricy S, Marjańska M, Branzoli F, Sanson M. In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH-Mutant Diffuse Gliomas: The IDASPE Prospective Study. Neurology 2023; 100:e94-e106. [PMID: 36180241 PMCID: PMC9827125 DOI: 10.1212/wnl.0000000000201137] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2021] [Accepted: 07/05/2022] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND AND OBJECTIVES D-2-hydroxyglutarate (2HG) characterizes IDH-mutant gliomas and can be detected and quantified with edited MRS (MEGA-PRESS). In this study, we investigated the clinical, radiologic, and molecular parameters affecting 2HG levels. METHODS MEGA-PRESS data were acquired in 71 patients with glioma (24 untreated, 47 treated) on a 3 T system. Eighteen patients were followed during cytotoxic (n = 12) or targeted (n = 6) therapy. 2HG was measured in tumor samples using gas chromatography coupled to mass spectrometry (GCMS). RESULTS MEGA-PRESS detected 2HG with a sensitivity of 95% in untreated patients and 62% in treated patients. Sensitivity depended on tumor volume (>27 cm3; p = 0.02), voxel coverage (>75%; p = 0.002), and expansive presentation (defined by equal size of T1 and FLAIR abnormalities, p = 0.04). 2HG levels were positively correlated with IDH-mutant allelic fraction (p = 0.03) and total choline levels (p < 0.001) and were higher in IDH2-mutant compared with IDH1 R132H-mutant and non-R132H IDH1-mutant patients (p = 0.002). In patients receiving IDH inhibitors, 2HG levels decreased within a few days, demonstrating the on-target effect of the drug, but 2HG level decrease did not predict tumor response. Patients receiving cytotoxic treatments showed a slower decrease in 2HG levels, consistent with tumor response and occurring before any tumor volume change on conventional MRI. At progression, 1p/19q codeleted gliomas, but not the non-codeleted, showed detectable in vivo 2HG levels, pointing out to different modes of progression characterizing these 2 entities. DISCUSSION MEGA-PRESS edited MRS allows in vivo monitoring of 2-hydroxyglutarate, confirming efficacy of IDH inhibition and suggests different patterns of tumor progression in astrocytomas compared with oligodendrogliomas.
Collapse
Affiliation(s)
- Anna Luisa Di Stefano
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Lucia Nichelli
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Giulia Berzero
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Romain Valabregue
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Mehdi Touat
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Laurent Capelle
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Clément Pontoizeau
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Franck Bielle
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Julie Lerond
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Marine Giry
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Chiara Villa
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Bertrand Baussart
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Caroline Dehais
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Damien Galanaud
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Capucine Baldini
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Julien Savatovsky
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Frédéric Dhermain
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Dinesh K Deelchand
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Chris Ottolenghi
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Stéphane Lehéricy
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Małgorzata Marjańska
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Francesca Branzoli
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - Marc Sanson
- From the Sorbonne Université (A.L.D.S.,M.D.P.D., L.N., M.D.P.D., J.L., M.G., S.L., Francesca Branzoli), Inserm, CNRS, Paris Brain Institute-Institut du Cerveau (ICM), Paris, France. Equipe labellisée LNCC; Service de Neurologie 2-Mazarin (A.L.D.S.,M.D.P.D., M.D.P.D., C.D.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Neuroradiologie Diagnostique et Interventionnelle (L.N., D.G., S.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Centre de NeuroImagerie de Recherche (CENIR) (R.V., S.L., Francesca Branzoli), Institut du Cerveau (ICM), Paris, France; Service de Neurochirurgie (L.C., B.B.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Service de Biochimie Métabolique (C.P.), AP-HP, Hôpital Necker, Paris, France; Laboratoire R Escourolle (J.L.), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Drug Development Department (DITEP) (C.B.), Gustave Roussy, Villejuif, France; Service de Radiologie (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Radiotherapy Department (F.D.), Gustave Roussy University Hospital, Villejuif, Cedex, France; Center for Magnetic Resonance Research (D.K.D., M.M.), Department of Radiology, Minneapolis, MN; and OncoNeuroTek Tumor Bank (M.D.P.D.), Institut du Cerveau et de la Moelle épinière (ICM), Paris, France.
| |
Collapse
|
6
|
Tran S, Thomas A, Touat M, Karachi C, Lozano F, Mokhtari K, Dehais C, Feuvret L, Carpentier C, Giry M, Doukani H, Lerond J, Marie Y, Sanson M, Idbaih A, Carpentier A, Hoang-Xuan K, Capelle L, Bielle F. OS07.1.A A threshold of mitotic activity and post-surgery residual volume are independant prognostic factors in astrocytoma IDH-mutant. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The distinction between grade 2 and 3 is instrumental to choose between observational follow-up and adjuvant treatment in resected astrocytoma IDH-mutant. However, criteria of grade 2 versus 3 have not been updated since the WHO 2007 classification. There is no consensus on the method of evaluation of the mitotic activity or a cut-off of mitoses separating grade 2 and grade 3 tumors. The objectives were to evaluate the maximal mitotic activity on a series of resected astrocytoma IDH-mutant and assess its prognostic impact on survival.
Material and Methods
Maximal mitotic activity on consecutive high power fields corresponding to 3 mm2 was examined in 118 lower-grade astrocytoma IDH-mutant. The prognostic value for time-to-treatment (TTT) and overall survival (OS) of mitotic activity and other putative prognostic factors (including age, performance status, pre-surgical tumor volume, plurilobar involvement, post-surgical residual tumor volume, midline involvement) was assessed in tumors with (i) ATRX loss, and (ii) without CDKN2A homozygous deletion, lesional enhancement, histological necrosis nor microvascular proliferation.
Results
Among the 75 (64%) of tumors which had gone through observational follow-up after resection, the maximal mitotic activity, the post-surgical residual volume and the plurilobar involvement were independent prognostic factors of TTT (p < 0.0001). A threshold of mitotic activity for grade 2 was fitted on TTT and OS prognosis. Using this threshold, patients with “grade 2 tumors” had a median TTT of 55 months versus 19 months for “grade 3” (p = 0.0057) and a median OS of 102 months versus 73 months respectively (p = 0.001). Residual volume < 1 cm3 was associated with longer OS (113 months versus 88 months, p = 0.0021).
Conclusion
Mitotic activity and post-surgical residual volume can be combined to evaluate prognosis in resected astrocytoma IDH-mutant and could select the best candidates for observational follow-up.
Collapse
Affiliation(s)
- S Tran
- Pitie-Salpetriere Hospital, Department of Neuropathology , Paris , France
| | - A Thomas
- Institut de Cancérologie Strasbourg Europe, Department of Radiation Oncology , Strasbourg , France
| | - M Touat
- Pitie-Salpetriere Hospital, Department of Neurology Mazarin , Paris , France
| | - C Karachi
- Pitie-Salpetriere Hospital, Department of Neurosurgery , Paris , France
| | - F Lozano
- Pitie-Salpetriere Hospital, Department of Neurology Mazarin , Paris , France
| | - K Mokhtari
- Pitie-Salpetriere Hospital, Department of Neuropathology , Paris , France
| | - C Dehais
- Pitie-Salpetriere Hospital, Department of Neurology Mazarin , Paris , France
| | - L Feuvret
- Pitie-Salpetriere Hospital, Department of Radiotherapy , Paris , France
| | - C Carpentier
- Sorbonne Universite, Paris Brain Institute - ICM , Paris , France
| | - M Giry
- Sorbonne Universite, Paris Brain Institute - ICM , Paris , France
| | - H Doukani
- Sorbonne Universite INSERM, Plateforme post-genomique de la Pitie-Salpetriere , Paris , France
| | - J Lerond
- Sorbonne Universite, Paris Brain Institute - ICM , Paris , France
| | - Y Marie
- Sorbonne Universite, Paris Brain Institute - ICM , Paris , France
| | - M Sanson
- Pitie-Salpetriere Hospital, Department of Neurology Mazarin , Paris , France
| | - A Idbaih
- Pitie-Salpetriere Hospital, Department of Neurology Mazarin , Paris , France
| | - A Carpentier
- Pitie-Salpetriere Hospital, Department of Neurosurgery , Paris , France
| | - K Hoang-Xuan
- Pitie-Salpetriere Hospital, Department of Neurology Mazarin , Paris , France
| | - L Capelle
- Pitie-Salpetriere Hospital, Department of Neurosurgery , Paris , France
| | - F Bielle
- Pitie-Salpetriere Hospital, Department of Neuropathology , Paris , France
| |
Collapse
|
7
|
Lerond J, Morisse MC, Letourneur Q, Gimonnet C, Navarro S, Gaspar C, Idbaih A, Bielle F. Immune Microenvironment and Lineage Tracing Help to Decipher Rosette-Forming Glioneuronal Tumors: A Multi-Omics Analysis. J Neuropathol Exp Neurol 2022; 81:873-884. [PMID: 35984315 DOI: 10.1093/jnen/nlac074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Rosette-forming glioneuronal tumors (RGNT) are rare low-grade primary central nervous system (CNS) tumors. The methylation class (MC) RGNT (MC-RGNT) delineates RGNT from other neurocytic CNS tumors with similar histological features. We performed a comprehensive molecular analysis including whole-exome sequencing, RNAseq, and methylome on 9 tumors with similar histology, focusing on the immune microenvironment and cell of origin of RGNT. Three RGNT in this cohort were plotted within the MC-RGNT and characterized by FGFR1 mutation plus PIK3CA or NF1 mutations. RNAseq analysis, validated by immunohistochemistry, identified 2 transcriptomic groups with distinct immune microenvironments. The "cold" group was distinguishable by a low immune infiltration and included the 3 MC-RGNT and 1 MC-pilocytic astrocytoma; the "hot" group included other tumors with a rich immune infiltration. Gene set enrichment analysis showed that the "cold" group had upregulated NOTCH pathway and mainly oligodendrocyte precursor cell and neuronal phenotypes, while the "hot" group exhibited predominantly astrocytic and neural stem cell phenotypes. In silico deconvolution identified the cerebellar granule cell lineage as a putative cell of origin of RGNT. Our study identified distinct tumor biology and immune microenvironments as key features relevant to the pathogenesis and management of RGNT.
Collapse
Affiliation(s)
- Julie Lerond
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC Curamus, Paris, France
| | - Mony Chenda Morisse
- AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
| | | | | | - Soledad Navarro
- AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurochirurgie, Paris, France
| | - Cassandra Gaspar
- Sorbonne Université, Inserm, UMS Production et Analyse des données en Sciences de la vie et en Santé, PASS, Plateforme Post-génomique de la Pitié-Salpêtrière, Paris, France
| | - Ahmed Idbaih
- Sorbonne Université, AP-HP, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
| | - Franck Bielle
- Sorbonne Université, AP-HP, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neuropathologie, Paris, France.,AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Onconeurotek, Paris, France
| |
Collapse
|
8
|
Peyre M, Miyagishima D, Bielle F, Chapon F, Sierant M, Venot Q, Lerond J, Marijon P, Abi-Jaoude S, Le Van T, Labreche K, Houlston R, Faisant M, Clémenceau S, Boch AL, Nouet A, Carpentier A, Boetto J, Louvi A, Kalamarides M. Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations. N Engl J Med 2021; 385:996-1004. [PMID: 34496175 PMCID: PMC8606022 DOI: 10.1056/nejmoa2100440] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND Cerebral cavernous malformations (CCMs) are common sporadic and inherited vascular malformations of the central nervous system. Although familial CCMs are linked to loss-of-function mutations in KRIT1 (CCM1), CCM2, or PDCD10 (CCM3), the genetic cause of sporadic CCMs, representing 80% of cases, remains incompletely understood. METHODS We developed two mouse models harboring mutations identified in human meningiomas with the use of the prostaglandin D2 synthase (PGDS) promoter. We performed targeted DNA sequencing of surgically resected CCMs from patients and confirmed our findings by droplet digital polymerase-chain-reaction analysis. RESULTS We found that in mice expressing one of two common genetic drivers of meningioma - Pik3ca H1047R or AKT1 E17K - in PGDS-positive cells, a spectrum of typical CCMs develops (in 22% and 11% of the mice, respectively) instead of meningiomas, which prompted us to analyze tissue samples from sporadic CCMs from 88 patients. We detected somatic activating PIK3CA and AKT1 mutations in 39% and 1%, respectively, of lesion tissue from the patients. Only 10% of lesions harbored mutations in the CCM genes. We analyzed lesions induced by the activating mutations Pik3ca H1074R and AKT1 E17K in mice and identified the PGDS-expressing pericyte as the probable cell of origin. CONCLUSIONS In tissue samples from sporadic CCMs, mutations in PIK3CA were represented to a greater extent than mutations in any other gene. The contribution of somatic mutations in the genes that cause familial CCMs was comparatively small. (Funded by the Fondation ARC pour la Recherche contre le Cancer and others.).
Collapse
Affiliation(s)
- Matthieu Peyre
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Danielle Miyagishima
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Franck Bielle
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Françoise Chapon
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Michael Sierant
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Quitterie Venot
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Julie Lerond
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Pauline Marijon
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Samiya Abi-Jaoude
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Tuan Le Van
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Karim Labreche
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Richard Houlston
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Maxime Faisant
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Stéphane Clémenceau
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Anne-Laure Boch
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Aurelien Nouet
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Alexandre Carpentier
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Julien Boetto
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Angeliki Louvi
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| | - Michel Kalamarides
- From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.)
| |
Collapse
|
9
|
Boetto J, Lerond J, Peyre M, Tran S, Marijon P, Kalamarides M, Bielle F. GAB1 overexpression identifies hedgehog-activated anterior skull base meningiomas. Neuropathol Appl Neurobiol 2021; 47:748-755. [PMID: 34056767 DOI: 10.1111/nan.12740] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 05/21/2021] [Accepted: 05/22/2021] [Indexed: 11/28/2022]
Abstract
AIMS Mutations activating the hedgehog (Hh) signalling pathway have been described in anterior skull base meningiomas, raising hope for the use of targeted therapies. However, identification of Hh-activated tumours is hampered by the lack of a reliable immunohistochemical marker. We report the evaluation of GAB1, an immunohistochemical marker used to detect Hh pathway activation in medulloblastoma, as a potential marker of Hh-activated meningiomas. METHODS GAB1 staining was compared to SMO mutation detection with Sanger and NGS techniques as well as Hh pathway activation study through mRNA expression level analyses in a discovery set of 110 anterior skull base meningiomas and in a prospective validation set of 21 meningiomas. RESULTS Using an expression score ranging from 0 to 400, we show that a cut-off score of 250 lead to excellent detection of Hh pathway mutations (sensitivity 100%, specificity 86%). The prospective validation set confirmed the excellent negative predictive value of GAB1 to exclude Hh-independent meningiomas. We describe a large series of 32 SMO-mutant meningiomas and define multiple ways of Hh activation, either through somatic mutations or associated with mutually co-exclusive sonic hedgehog (SHH) or Indian hedgehog (IHH) overexpression independent of the mutations. CONCLUSION The assessment of GAB1 expression by an immunohistochemical score is a fast and cost-efficient tool to screen anterior skull base meningiomas for activation of the Hh pathway. It could facilitate the identification of selected cases amenable to sequencing for Hh pathway genes as predictive markers for targeted therapy.
Collapse
Affiliation(s)
- Julien Boetto
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital Center, Montpellier, France.,ICM INSERM U1127 CNRS UMR 7225, Paris Brain Institute, Paris, France
| | - Julie Lerond
- ICM INSERM U1127 CNRS UMR 7225, Paris Brain Institute, Paris, France.,SiRIC CURAMUS (Cancer United Research Associating Medicine, University & Society) - site de recherche intégrée sur le cancer IUC - APHP.6 - Sorbonne Université, Paris, France
| | - Matthieu Peyre
- ICM INSERM U1127 CNRS UMR 7225, Paris Brain Institute, Paris, France.,Department of Neurosurgery, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.,Sorbonne Université, UPMC Univ Paris 06, Paris, France
| | - Suzanne Tran
- Sorbonne Université, UPMC Univ Paris 06, Paris, France.,Department of Neuropathology, AP-HP, Hôpital Pitié Salpêtrière, Paris, France
| | - Pauline Marijon
- ICM INSERM U1127 CNRS UMR 7225, Paris Brain Institute, Paris, France.,Department of Neurosurgery, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Michel Kalamarides
- ICM INSERM U1127 CNRS UMR 7225, Paris Brain Institute, Paris, France.,Department of Neurosurgery, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.,Sorbonne Université, UPMC Univ Paris 06, Paris, France
| | - Franck Bielle
- ICM INSERM U1127 CNRS UMR 7225, Paris Brain Institute, Paris, France.,SiRIC CURAMUS (Cancer United Research Associating Medicine, University & Society) - site de recherche intégrée sur le cancer IUC - APHP.6 - Sorbonne Université, Paris, France.,Sorbonne Université, UPMC Univ Paris 06, Paris, France.,Department of Neuropathology, AP-HP, Hôpital Pitié Salpêtrière, Paris, France.,Onconeurotek, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France
| |
Collapse
|
10
|
Di Stefano AL, Picca A, Saragoussi E, Bielle F, Ducray F, Villa C, Eoli M, Paterra R, Bellu L, Mathon B, Capelle L, Bourg V, Gloaguen A, Philippe C, Frouin V, Schmitt Y, Lerond J, Leclerc J, Lasorella A, Iavarone A, Mokhtari K, Savatovsky J, Alentorn A, Sanson M. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. Neuro Oncol 2021; 22:1614-1624. [PMID: 32413119 DOI: 10.1093/neuonc/noaa121] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Actionable fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil protein 3 fusions (F3T3) are found in approximately 3% of gliomas, but their characteristics and prognostic significance are still poorly defined. Our goal was to characterize the clinical, radiological, and molecular profile of F3T3 positive diffuse gliomas. METHODS We screened F3T3 fusion by real-time (RT)-PCR and FGFR3 immunohistochemistry in a large series of gliomas, characterized for main genetic alterations, histology, and clinical evolution. We performed a radiological and radiomic case control study, using an exploratory and a validation cohort. RESULTS We screened 1162 diffuse gliomas (951 unselected cases and 211 preselected for FGFR3 protein immunopositivity), identifying 80 F3T3 positive gliomas. F3T3 was mutually exclusive with IDH mutation (P < 0.001) and EGFR amplification (P = 0.01), defining a distinct molecular cluster associated with CDK4 (P = 0.04) and MDM2 amplification (P = 0.03). F3T3 fusion was associated with longer survival for the whole series and for glioblastomas (median overall survival was 31.1 vs 19.9 mo, P = 0.02) and was an independent predictor of better outcome on multivariate analysis.F3T3 positive gliomas had specific MRI features, affecting preferentially insula and temporal lobe, and with poorly defined tumor margins. F3T3 fusion was correctly predicted by radiomics analysis on both the exploratory (area under the curve [AUC] = 0.87) and the validation MRI (AUC = 0.75) cohort. Using Cox proportional hazards models, radiomics predicted survival with a high C-index (0.75, SD 0.04), while the model combining clinical, genetic, and radiomic data showed the highest C-index (0.81, SD 0.04). CONCLUSION F3T3 positive gliomas have distinct molecular and radiological features, and better outcome.
Collapse
Affiliation(s)
- Anna Luisa Di Stefano
- Inserm Unit 1127, Sorbonne University, Institute of the Brain and Spinal Cord, Paris, France.,SiRIC CURAMUS, LNCC (équipe labellisée).,Department of Neuropathology 2, Pitié-Salpêtrière Hospital,Paris, France.,Department of Neurology, Foch Hospital, Suresnes, France
| | - Alberto Picca
- C. Mondino Foundation, Pavia, Italy.,Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Edouard Saragoussi
- Department of Radiology, Adolphe de Rothschild Ophthalmological Foundation, Paris, France
| | - Franck Bielle
- Department of Neuropathology, Pitié Salpêtrière-Charles Foix, Paris, France
| | - Francois Ducray
- Department of Neuro-Oncology, Civil Hospice of Lyon, University Claude Bernard Lyon 1, Department of Cancer Cell Plasticity, Cancer Research Center of Lyon, Lyon, France.,POLA Network
| | - Chiara Villa
- Department of Pathology, Foch Hospital, Suresnes, France
| | - Marica Eoli
- Unit of Molecular Neuro-Oncology, Carlo Besta Neurological Institute, Milan, Italy
| | - Rosina Paterra
- Unit of Molecular Neuro-Oncology, Carlo Besta Neurological Institute, Milan, Italy
| | - Luisa Bellu
- Department of Neuropathology 2, Pitié-Salpêtrière Hospital,Paris, France
| | - Bertrand Mathon
- Department of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France
| | - Laurent Capelle
- Department of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France
| | - Véronique Bourg
- Department of Neurology, Pasteur 2 Hospital, Nice Côte D'Azur University, Nice, France
| | - Arnaud Gloaguen
- Signals and Systems Laboratory, Paris-Saclay University, Gif-sur-Yvette, France.,Neurospin, French Atomic Energy Commission, Paris-Saclay University, Gif-sur-Yvette, France
| | - Cathy Philippe
- Neurospin, French Atomic Energy Commission, Paris-Saclay University, Gif-sur-Yvette, France
| | - Vincent Frouin
- Neurospin, French Atomic Energy Commission, Paris-Saclay University, Gif-sur-Yvette, France
| | - Yohann Schmitt
- Inserm Unit 1127, Sorbonne University, Institute of the Brain and Spinal Cord, Paris, France.,SiRIC CURAMUS, LNCC (équipe labellisée)
| | - Julie Lerond
- Inserm Unit 1127, Sorbonne University, Institute of the Brain and Spinal Cord, Paris, France.,SiRIC CURAMUS, LNCC (équipe labellisée).,Department of Neuropathology, Pitié Salpêtrière-Charles Foix, Paris, France
| | - Julie Leclerc
- Inserm Unit 1127, Sorbonne University, Institute of the Brain and Spinal Cord, Paris, France.,SiRIC CURAMUS, LNCC (équipe labellisée).,Department of Neuropathology, Pitié Salpêtrière-Charles Foix, Paris, France
| | - Anna Lasorella
- Institute for Cancer Genetics, Columbia University, New York, New York, USA.,Department of Pathology and Cell Biology, Columbia University, New York, New York, USA.,Department of Pediatrics, Columbia University, New York, New York, USA
| | - Antonio Iavarone
- Institute for Cancer Genetics, Columbia University, New York, New York, USA.,Department of Pathology and Cell Biology, Columbia University, New York, New York, USA.,Department of Neurology, Columbia University, New York, New York, USA
| | - Karima Mokhtari
- Department of Neuropathology, Pitié Salpêtrière-Charles Foix, Paris, France
| | - Julien Savatovsky
- Department of Radiology, Adolphe de Rothschild Ophthalmological Foundation, Paris, France
| | - Agusti Alentorn
- Inserm Unit 1127, Sorbonne University, Institute of the Brain and Spinal Cord, Paris, France.,SiRIC CURAMUS, LNCC (équipe labellisée).,Department of Neuropathology 2, Pitié-Salpêtrière Hospital,Paris, France
| | - Marc Sanson
- Inserm Unit 1127, Sorbonne University, Institute of the Brain and Spinal Cord, Paris, France.,SiRIC CURAMUS, LNCC (équipe labellisée).,Department of Neuropathology 2, Pitié-Salpêtrière Hospital,Paris, France.,OncoNeuroTek, Institute of the Brain and Spinal Cord, Paris, France
| | | |
Collapse
|
11
|
Tran S, Mathon B, Morcos-Sauvain E, Lerond J, Navarro V, Bielle F. [Neuropathology of epilepsy]. Ann Pathol 2020; 40:447-460. [PMID: 33092907 DOI: 10.1016/j.annpat.2020.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Revised: 08/02/2020] [Accepted: 08/17/2020] [Indexed: 10/23/2022]
Abstract
The neuropathology of epilepsy aims at diagnosing the cerebral lesions underlying epilepsy that are obtained from epilepsy surgery, or rarely from biopsy or autopsy. The main histopathological and immunohistochemical characteristics of several entities are described: epilepsy-associated hippocampal sclerosis, long-term epilepsy-associated tumours, cortical malformations, vascular malformations, glial scars, encephalitides, and focal neuronal lipofuscinosis. The diagnostic approach, the differential diagnosis and the histochemical and immunohistochemical tools are detailed in order to provide the pathologist with a summarized toolkit to handle the broad range of epileptogenic lesions.
Collapse
Affiliation(s)
- Suzanne Tran
- Département de neuropathologie, laboratoire Escourolle, hôpital de la Pitié-Salpêtrière, AP-HP, 46-83, boulevard de l'Hôpital, 75013 Paris, France
| | - Bertrand Mathon
- Inserm, CNRS, Paris brain institute, ICM, Sorbonne université, AP-HP, Paris, France; Service de neurochirurgie, hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France
| | - Elise Morcos-Sauvain
- Département de neuropathologie, laboratoire Escourolle, hôpital de la Pitié-Salpêtrière, AP-HP, 46-83, boulevard de l'Hôpital, 75013 Paris, France
| | - Julie Lerond
- Inserm, CNRS, Paris brain institute, ICM, Sorbonne université, AP-HP, Paris, France; SiRIC curamus (cancer united research associating medicine, university & society), site de recherche intégrée sur le cancer IUC, Sorbonne université, AP-HP, Paris, France
| | - Vincent Navarro
- Inserm, CNRS, Paris brain institute, ICM, Sorbonne université, AP-HP, Paris, France; Service de neurologie, hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France; Centre de référence des épilepsies rares, Paris, France
| | - Franck Bielle
- Département de neuropathologie, laboratoire Escourolle, hôpital de la Pitié-Salpêtrière, AP-HP, 46-83, boulevard de l'Hôpital, 75013 Paris, France; Inserm, CNRS, Paris brain institute, ICM, Sorbonne université, AP-HP, Paris, France; SiRIC curamus (cancer united research associating medicine, university & society), site de recherche intégrée sur le cancer IUC, Sorbonne université, AP-HP, Paris, France.
| |
Collapse
|
12
|
Nichelli L, Branzoli F, Valabregue R, Capelle L, Ottolenghi C, Bielle F, Lerond J, Giry M, Villa C, Galanaud D, Lehéricy S, Marjańska M, Sanson M, Di Stefano A. PL1.2 Multiparametric assessment of factors influencing 2 HG accumulation in diffuse brain gliomas. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
2-hydroxyglutarate (2HG) can be detected non-invasively in IDH-mutant gliomas by in vivo magnetic resonance spectroscopy (MRS). We investigated factors affecting 2 HG accumulation and explored the prognostic value of 2 HG detection in IDH mutant gliomas and 2 HG variations during anti-cancer therapies.
MATERIAL AND METHODS
We prospectively scanned by MEGA-PRESS 70 glioma patients (24 before surgery and 46 IDH mutant operated glioma) and measured 2HG. CRLB cut-off was 50%. We followed up 9 IDH mutant patients during radiotherapy and chemotherapy.We analyzed radiological parameters (tumor and cystic/necrotic volumes, fractions of VOI filled with tumor, spectroscopic profile, “infiltrative” versus “expansive” morphology, contrast-enhancement) and genetic profile (IDH1, IDH2, 1p19q codeletion). 2HG concentrations in plasma, urine, and surgical obtained samples were measured by gas chromatography-mass spectrometry (GC-MS).
RESULTS
MEGA-PRESS sequence detected 2HG with a sensitivity of 95% in untreated patients, and of 69% in pre-treated patient. Positive predictive value was 100% in both groups. 2HG was lower in pre-treated IDH mutant gliomas (1.1 versus 2.3 mM, P=0.02) and decreased rapidly during radiotherapy and chemotherapy before any radiological change. 2HG detection was positively correlated with tumor volume (P=0.02), choline measurements (r=0.58 P<0.0001), cellular density (measured by restricted diffusivity, Pearson r -0.40 P=0.01), “expansive” presentation, mutated reads/total reads ratio by NGS and was inversely correlated with Myo-inositol (Pearson R -0.29 P=0.03) and cystic/necrotic areas (P=0.04). 2HG by MRS positively correlated with urine 2HG (r=0.80 P=0.003). 2 HG was higher in IDH2 mutant (4.7 versus 2.4 Mm, P=0.02) and lower in non R132H IDH1 mutant (1.12 mM P=0.004). Among IDH mutant glioma patients, 2 HG detection was associated with longer survival (HR 0.09; 95%CI 0.018–0.52).
CONCLUSION
Tumor volume, cellular density, previous radio- and chemotherapy and genetic features determine 2 HG detection in IDH mutant gliomas. 2 HG detection is associated with better outcome and can be reliably monitored during anti-cancer treatments.
Collapse
Affiliation(s)
- L Nichelli
- Institut du Cerveau et de la Moelle Epinière- ICM, Centre de NeuroImagerie de Recherche CENIR, Paris, France
- Department of Diagnostic Imaging, University of Modena and Reggio Emilia, Modena, Italy
| | - F Branzoli
- Institut du Cerveau et de la Moelle Epinière- ICM, Centre de NeuroImagerie de Recherche CENIR, Paris, France
- Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - R Valabregue
- Institut du Cerveau et de la Moelle Epinière- ICM, Centre de NeuroImagerie de Recherche CENIR, Paris, France
- Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - L Capelle
- University Hospitals Pitié Salpêtrière - Charles Foix Department of Neurosurgery, Paris, France
| | - C Ottolenghi
- Hôpital Necker and Université Paris Descartes Service de Biochimie Métabolique, Paris, France
| | - F Bielle
- Service de Neuropathologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France
- Institut du Cerveau et de la Moelle Epinière- ICM, Paris, France
| | - J Lerond
- Institut du Cerveau et de la Moelle Epinière- ICM, Paris, France
| | - M Giry
- Institut du Cerveau et de la Moelle Epinière- ICM, Paris, France
| | - C Villa
- Foch Hospital, Service d’Anatomie et Cytologie pathologiques, Suresnes, Paris, France
| | - D Galanaud
- University Hospitals Pitié Salpêtrière - Charles Foix Department of Neurordiology, Paris, France
- Institut du Cerveau et de la Moelle Epinière- ICM, Centre de NeuroImagerie de Recherche CENIR, Paris, France
| | - S Lehéricy
- Institut du Cerveau et de la Moelle Epinière- ICM, Centre de NeuroImagerie de Recherche CENIR, Paris, France
- Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICNRS UMR 7225, Paris, France
| | - M Marjańska
- Center for Magnetic Resonance Research Department of Radiology, Minneapolis, MN, United States
| | - M Sanson
- University Hospitals Pitié Salpêtrière - Charles Foix Department of Neurology, Paris, France
- Institut du Cerveau et de la Moelle Epinière- ICM, Paris, France
| | - A Di Stefano
- Foch Hospital, Service de Neurologie, Suresnes, Paris, France
- University Hospitals Pitié Salpêtrière - Charles Foix Department of Neurology, Paris, France
| |
Collapse
|
13
|
Khalki L, Sadlaoud K, Lerond J, Coq JO, Brezun JM, Vinay L, Coulon P, Bras H. Changes in innervation of lumbar motoneurons and organization of premotor network following training of transected adult rats. Exp Neurol 2018; 299:1-14. [DOI: 10.1016/j.expneurol.2017.09.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 09/04/2017] [Accepted: 09/06/2017] [Indexed: 12/29/2022]
|
14
|
Schwan R, Tadri M, Zuily S, Lerond J, Laprevote V. Efficacy of plasma exchange in pharmaco-resistant acute mania in systemic lupus erythematosus. J Neuropsychiatry Clin Neurosci 2013; 25:E02-3. [PMID: 23487201 DOI: 10.1176/appi.neuropsych.11120373] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- R Schwan
- University Hospital of Psychiatrie and Psychothérapie, Laxou, France
| | | | | | | | | |
Collapse
|
15
|
Hingray C, Maillard L, Hubsch C, Vignal JP, Bourgognon F, Laprevote V, Lerond J, Vespignani H, Schwan R. Psychogenic nonepileptic seizures: characterization of two distinct patient profiles on the basis of trauma history. Epilepsy Behav 2011; 22:532-6. [PMID: 21962755 DOI: 10.1016/j.yebeh.2011.08.015] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2011] [Revised: 08/10/2011] [Accepted: 08/16/2011] [Indexed: 10/17/2022]
Abstract
This prospective study investigated and compared psychiatric features of 25 consecutive patients with psychogenic nonepileptic seizures (PNES) on the basis of presence of reported trauma. The "trauma" group comprised 19 patients (76%) and the "no-trauma" group comprised 6 patients (34%). We compared history of PNES, psychiatric comorbidity, alexithymia, and symptoms of dissociation. The study clearly characterized two distinct profiles of patients with PNES on the basis of trauma history. Patients with trauma had at least one psychiatric comorbidity or antecedent (vs 0% in the no-trauma group NT, P<0.001) and a higher median score of dissociation (P<0.001). Patients without trauma had more frequent "frustration situations" as a factor triggering PNES and subsequent sick leaves as perpetuating factors (P=0.001). Trauma antecedents correlated with a high rate of psychiatric comorbidity and a strong dissociative mechanism. Patients without trauma had no psychiatric comorbidity and a weaker dissociative mechanism.
Collapse
Affiliation(s)
- C Hingray
- CSAPA (Health Care Centre of Accompaniment and Prevention in Addictology), University Hospital of Nancy, Nancy, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Jacquet H, Demily C, Houy E, Hecketsweiler B, Bou J, Raux G, Lerond J, Allio G, Haouzir S, Tillaux A, Bellegou C, Fouldrin G, Delamillieure P, Ménard JF, Dollfus S, D'Amato T, Petit M, Thibaut F, Frébourg T, Campion D. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry 2005; 10:479-85. [PMID: 15494707 DOI: 10.1038/sj.mp.4001597] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
DNA sequence variations within the 22q11 DiGeorge chromosomal region are likely to confer susceptibility to psychotic disorders. In a previous report, we identified several heterozygous alterations, including a complete deletion, of the proline dehydrogenase (PRODH) gene, which were associated with moderate hyperprolinemia in a subset of DSM III schizophrenic patients. Our objective was (i) to determine whether hyperprolinemia is associated with increased susceptibility for any of three psychiatric conditions (schizophrenia, schizoaffective disorder and bipolar disorder) and (ii) to establish a correlation between hyperprolinemia and PRODH genotypes. We have conducted a case-control study including 114 control subjects, 188 patients with schizophrenia, 63 with schizoaffective disorder and 69 with bipolar disorder. We report that, taking into account a confounding effect due to valproate treatment, hyperprolinemia is a risk factor for DSM IIIR schizoaffective disorder (P=0.02, Odds ratio=4.6, 95% confidence interval 1.3-16.3). We did not detect 22q11 interstitial deletions associated with the DiGeorge syndrome among the 320 patients of our sample and we found no association between common PRODH polymorphisms and any of the psychotic disorders. In contrast, we found that five rare PRODH alterations (including a complete PRODH deletion and four missense substitutions) were associated with hyperprolinemia. In several cases, two variations were present simultaneously, either in cis or trans in the same subject. A total of 11 from 30 hyperprolinemic subjects bore at least one genetic variation associated with hyperprolinemia. This study demonstrates that moderate hyperprolinemia is an intermediate phenotype associated with certain forms of psychosis.
Collapse
Affiliation(s)
- H Jacquet
- Inserm U614, IFRMP, Faculté de Médecine, Rouen 76183, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Poulet E, Brunelin J, Boeuve C, Lerond J, D'Amato T, Dalery J, Saoud M. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. Eur Psychiatry 2005; 19:382-3. [PMID: 15363481 DOI: 10.1016/j.eurpsy.2004.06.021] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2004] [Revised: 06/08/2004] [Accepted: 06/14/2004] [Indexed: 12/24/2022] Open
Abstract
In a double blind controlled study, rTMS results in a similar antidepressant effect to sham in combination with paroxetine. Both groups had the same delay in scale's scores improvement. rTMS seems not to be efficient as an add-on treatment to pharmacological medication in non-resistant major depression.
Collapse
Affiliation(s)
- E Poulet
- EA 3092, Université Claude Bernard Lyon 1, 69677 Bron cedex, France
| | | | | | | | | | | | | |
Collapse
|